Acceleron Pharma — Investor Day (June 2021)
139 slides from Acceleron Pharma's investor day presentation, Jun 22, 2021
Slide 1: Research & Development Day 2021
R E S E A R C H & D E V E L O P M E N T D A Y 2 0 2 1 J U N E 2 2 , 2 0 2 1
Slide 2: Forward-Looking Statements
Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY’S STRATEGY, FUTURE PLANS AND PROSPECTS ACTUAL RESULTS COULD DIFFER MATERIALLY FROM THOSE INCLUDED IN THE FORWARD-LOOKING STATEMENTS DUE TO VARIOUS THE FORWARD-LOOKING STATEMENTS CONTAINED IN
Slide 3: Welcome and R&D Day Agenda
Welcome and R&D Day Agenda AC CE LERON VISION & S TRATEGY Our Approach to Research & Development 8:00 – 8:25 AM WHO GROUP 1 & 2 PUL MON ARY HYPER TENSION 8:25 – 10:00 AM S YS TEMIC SC LEROSIS- ASSOC IATED INTERS TITIAL LUNG DISE ASE 10:00 – 10:35 AM CL OSING R EMARKS AND Q&A SESSION10:35 – 11:00 AM
Slide 4: Habib Dable, President & CEO
— 7 >= ACCELERON ==" ACCELERO HABIB DABLE, PRESIDENT & CEO
Slide 5: Our Mission
O UR MI SSI ON
Slide 6: A Leader in Understanding the TGF-beta Superfamily
A Leader in Understanding the TGF-beta Superfamily More Than 18 Years of Focus The TGF-beta superfamily influences many biological processes, including cellular: Growth Differentiation Repair
Slide 7: Building a Global Acceleron for 2021 and Beyond
Building a Global Acceleron for 2021 and Beyond ACCELERON PHARMA RARE PULMONARY DISEASE HEMATOLOGY OUR PEOPLE “ACCELERATORS” TGF-BETA SUPERFAMILY RESEARCH BUSINESS DEVELOPMENT
Slide 8: Our Vision for Sotatercept in PAH
Our Vision for Sotatercept in Pulmonary Arterial Hypertension (PAH) BACKBONE THERAPY IN PAH
Slide 9: Expanding Our Vision for Sotatercept in Pulmonary Hypertension
Expanding our Vision for Sotatercept in Pulmonary Hypertension GROUP 1 Pulmonary Arterial Hypertension GROUP 2 Left Heart Disease GROUP 3 Interstitial Lung Disease TBD Program Status Phase 3 Development Underway Phase 2 Proof of Concept Trial Planned Scientific and Preclinical Evaluation Ongoing Cpc
Slide 10: ACE-1334 Adds Second Program to Build Rare Pulmonary Franchise
ACE-1334 Adds Second Program to Build Franchise in Rare Pulmonary sotatercept PULMONARY ACE-1334 >50,000 patients in the US and EU + WHO Group 1 WHO Group 2
Slide 11: Future Royalties from REBLOZYL Provide a Strong Foundation for Growth
Future Royalties from REBLOZYL® Provide a Strong Foundation for Growth B R I S T O L A N D A C C E L E R O N ’ S E S T I M AT E D A N N U A L P E A K S A L E S P O T E N T I A L $4 Billion+ 2029 non risk-adjusted peak sales estimate of $4 billion+ for REBLOZYL assumes success in current and potentia
Slide 12: Rare Pulmonary Leader
RARE PULMONARY LEADER RESEARCH BUSINESS DEVELOPMENT S O T A T E R C E P T • • A C E – 1 3 3 4 • Maximize REBLOZYL opportunity in collaboration with Bristol Myers Squibb Significant Growth Potential from Current Programs Along with Organic and Inorganic R&D N E W D I S E A S E A R E A S R A R E P U L
Slide 13: Jay Backstrom, Head of Research & Development
J AY B AC KS TR OM , MD , M PH H E A D O F R E S E A R C H & D E V E L O P M E N T
Slide 14: Our Science: Understanding the TGF-beta Superfamily Biology
Our Science: Understanding the TGF-beta Superfamily Biology Type 1 Type 2 Activin/GDF LigandsBMP/GDF Ligands Type 2Type 1 TGF-β Ligands Type 1 Type 2 Ligands Receptors
Slide 15: Versatility of the TGF-beta Superfamily Cellular Signaling Pathways
Versatility of the TGF-beta Superfamily Cellular Signaling Pathways Tamayo E, et al. Int. J. Mol. Sci. 2018, 19(12), 3928
Slide 16: Our Technology: Fusion Protein Traps
Our Technology: Engaging the TGF-beta Superfamily Biology with Fusion Protein Traps Acceleron’s Fusion Proteins
Slide 17: Our Approach: From Bench to Bedside and Back
Our Approach: From Bench to Bedside and Back
Slide 18: Luspatercept: Translation from Preclinical to Clinical Results
Luspatercept: Robust Translation from Preclinical to Clinical Results in Anemia Associated with Rare Blood Disorders RAP-536 | • luspatercept | •
Slide 19: Our Success: REBLOZYL
Our Success: REBLOZYL® The First and Only Approved Erythroid Maturation Agent +
Slide 20: Sotatercept: Translation from Preclinical to Clinical Results in PAH
Sotatercept: Robust Translation from Preclinical to Clinical Results in PAH RAP-011 | • sotatercept | • N Engl J Med
Slide 21: Significant Progress in Advancing Sotatercept in PH
Significant Progress in Advancing Sotatercept in Pulmonary Hypertension PULSAR SPECTRA 2017 2018 2019 2020 2021 Acceleron BREAKTHROUGH THERAPY DESIGNATION EMA PRI ME Z E N I T H
Slide 22: Scientific Rationale to Expand Sotatercept into WHO Group 2 PH and ACE-1334 in SSc-ILD
Strong Scientific Rationale and Preclinical Results to Expand Sotatercept into WHO Group 2 PH and Develop ACE-1334 in SSc-ILD • • • • P H A S E 2 T R I A L • • • A C E - 1 3 3 4 P H A S E 1 b / P H A S E 2 T R I A L
Slide 23: Building a Leading Rare Pulmonary Pipeline
Building a Leading Rare Pulmonary Pipeline Sotatercept PHASE 1 PHASE 2 PHASE 3 ACE-1334
Slide 24: Sotatercept in Pulmonary Hypertension
S O TATER C EPT IN P UL M ON AR Y HY P ER TEN SI ON Sotatercept is an investigational therapy that is not approved for any use in any country.
Slide 25: PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision
PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision ZENITH Patient Population Newly diagnosed stable double combination background therapy Stable background therapy (mono, double, or triple) Stable maximum background therapy
Slide 26: Our Guest Speakers
Our Guest Speakers M A R C H U M B E R T , M D , P H D * V A L L E R I E M C L A U G H L I N , M D * M A R D I G O M B E R G - M A I T L A N D , M D , M S c * *Drs. Gomberg, Humbert, and McLaughlin are investigators in multiple ongoing and planned Acceleron-sponsored clinical trials and are paid con
Slide 27: Marc Humbert, MD, PhD
Professor of Respiratory Medicine at the Université Paris-Saclay in Le Kremlin-Bicêtre, France; Director of the Department of Respiratory and Intensive Care Medicine, French Pulmonary Hypertension Reference Centre, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France *Dr. Humbert is an inv
Slide 28: PAH: A Disease of Cellular Proliferation and Vascular Remodeling
Pulmonary Arterial Hypertension: A Disease of Cellular Proliferation and Vascular Remodeling1,2 Definition: chronic pre-capillary pulmonary hypertension Cause: progressive structural remodeling of the pulmonary arteries Consequence: right heart failure and death Normal PAH J Signal Transduct Eur Res
Slide 29: Pulmonary Hypertension WHO Groups
Pulmonary Hypertension WHO Groups Eur Respir J. Circ Cardiovasc Qual Outcomes Group 1: PAH Group 2: Left Heart Disease Group 3: Lung Disease Group 4: CTEPH Group 5: Multifactorial Idiopathic Heritable Drug and Toxin Induced Associated With CTD, HIV, Portal Hypertension, CHD, or Schistosomiasis PVOD/
Slide 30: Current Approved Therapies Target Three Pathways in PAH
Current Approved Therapies Target Three Pathways of Endothelial Dysfunction in PAH
Slide 31: Key Measures for Risk Stratification From Registries
Summary of Key Measures for Risk Stratification From Registries noninvasive endpoints (FC, 6MWD, and BNP/NT-proBNP) REVEAL 2.02 SPAHR3 COMPERA4 FPHR5 FPHR 5 (noninvasive) Eur Respir J Chest Eur Heart J Eur Respir J Eur Respir J
Slide 32: PAH Treatment Algorithm
Pulmonary Arterial Hypertension Treatment Algorithm
Slide 33: Goals of Current Therapeutic Approaches
Goals of Current Therapeutic Approaches Include Delay of Functional Impairment and Improved Outcomes1,2 Time Fu nc ti on al C ap ac it y Ultimate goals: no functional impairment and outcome improvement Eur Respir Rev Eur Heart J Eur Respir Rev
Slide 34: How to Improve Patient Outcomes?
How to Improve Patient Outcomes?
Slide 35: Targeting Novel Pathways in PAH
Targeting Novel Pathways in PAH • Pulmonary artery endothelial cell dysfunction is a major abnormality identified in PAH • Strong translational research has identified a large number of novel targets in recent years • A major challenge will be to prioritize drug discovery and development Inflammatio
Slide 36: Identifying the Role of BMPR2 in Pulmonary Hypertension
Identifying the Role of BMPR2 in Pulmonary Hypertension • The BMP signaling pathway is defective in patients with familial primary pulmonary hypertension1 • Additional evidence of the role of BMP signaling pathway in PH, demonstrating reduced BMPR-II expression in primary pulmonary hypertension3 • F
Slide 37: Pulmonary Arterial Hypertension and Sotatercept
Pulmonary Arterial Hypertension and Sotatercept Pulmonary Arterial Hypertension Sotatercept et al. Circ Res , et al. N Engl J Med et al. Haematologica. et al. Sci Transl Med.
Slide 38: Preclinical Sotatercept Research
Preclinical Sotatercept Research • Treatment with sotatercept in preclinical experiments improved: – Hemodynamics – Right ventricular (RV) hypertrophy – RV function – Arteriolar remodeling • Sotatercept has been demonstrated preclinically to act via a mechanism linked to rebalancing pro- proliferati
Slide 39: Vallerie McLaughlin, MD
Professor of Cardiovascular Medicine; Director of the Pulmonary Hypertension Program University of Michigan *Dr. McLaughlin is an investigator in multiple ongoing and planned Acceleron- sponsored clinical trials and a paid consultant to Acceleron. VAL L ER I E M C L AU GH L IN , M D*
Slide 40: PULSAR Trial Design Schema
PULSAR Trial Design Schema A Phase 2, double-blind, randomized, placebo-controlled, parallel-group study K E Y I N C L U S I O N C R I T E R I A • • • • • – Randomization 3:3:4 (24 weeks) (ongoing) Trial currently in open-label extension phase 1:1
Slide 41: PULSAR Baseline Characteristics
PULSAR Baseline Characteristics (N=106) 3% Corrected congenital shunt-associated 7% Drug or toxin induced 16% Heritable 17% CTD- associated 58% Idiopathic PAH classification N Engl J Med Standard-of-care PAH therapy 9% Monotherapy 35% Double therapy 56% Triple therapy 53% FC II; 47% FC III Pulmonary
Slide 42: PULSAR 24-Week Primary and Key Secondary Endpoints
PULSAR 24-Week Primary and Key Secondary Endpoints Primary: Pulmonary Vascular Resistance Key Secondary: 6-Minute Walk Distance Change in 6MWD from baseline to Week 24 (LS mean ± SE) Placebo-corrected LS mean difference of 25 m (SE=11.1) at Week 24 (P=0.03*) N Engl J Med
Slide 43: PULSAR 24-Week Exploratory Analysis: Multicomponent Improvement
M E E T I N G A L L T H R E E C R I T E R I A : PULSAR 24-Week Exploratory Analysis: Multicomponent Improvement 3% 38% 0% 20% 40% 60% Placebo + SOC (n=32) Sotatercept + SOC all doses (n=74) P a ti e n ts WHO FC: improvement or maintenance of FC II NT-proBNP: ≥30% improvement 6MWD: ≥30-m improvement
Slide 44: ATS 2021: PULSAR Open-label Extension 48-week Interim Results
ATS 2021: PULSAR Study Open-label Extension 48-week Interim Results NT-proBNP (pg/mL) n=35 n=29 6MWD (m) Continuing 0.7 mg/kg + SOC Continuing 0.3 mg/kg + SOC Placebo + SOC / 0.7 mg/kg + SOC Placebo + SOC / 0.3 mg/kg + SOC n=29 n=27 n=14 n=13 n=15 n=12 n=42 n=40 n=32 n=32 n=15 n=15 n=15 n=14 n=34 n=
Slide 45: PULSAR Safety 24-week and 48-week OLE Summary
PULSAR Safety 24-week and 48-week OLE Summary TEAEs during the OLE period only, n (%) Continuing 0.3 mg/kg + SOC (n=31) Continuing 0.7 mg/kg + SOC (n=36) Placebo + SOC / 0.3 mg/kg + SOC (n=15) Placebo + SOC / 0.7 mg/kg + SOC (n=15) TEAEs Serious TEAEs Serious related TEAEs TEAEs leading to treatment
Slide 46: STELLAR Phase 3 Study
A Phase 3, randomized, double-blind, placebo- controlled study to compare the efficacy and safety of sotatercept versus placebo when added to background PAH therapy for the treatment of PAH Sotatercept is an investigational therapy that is not approved for any use in any country.
Slide 47: Key Inclusion Criteria for PULSAR Relative to STELLAR
Key Inclusion Criteria for PULSAR Relative to STELLAR Phase 3 Trial Key Inclusion Criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class II or III • Baseline RHC with PVR ≥5 Wood units • Baseline 6-minute walk distance 150-500 m • Stable treatment with background therapies, includi
Slide 48: STELLAR Phase 3 Trial Design Schema
STELLAR Phase 3 Trial Design Schema Randomization 1:1 N=284 Primary Endpoint Analysis ENROLLING
Slide 49: Primary Endpoint
Primary Endpoint Primary Endpoint • Change from baseline in 6-minute walk distance at week 24
Slide 50: Secondary Endpoints
Secondary Endpoints Secondary Endpoints • Multicomponent improvement endpoint measured by the proportion of participants achieving all of the following at 24 weeks as compared to baseline: Improvement in 6MWD (increase ≥ 30 m) Improvement in NT-proBNP (decrease in NT-proBNP ≥ 30% or maintenance/achi
Slide 51: HYPERION Phase 3 Study
A Phase 3, randomized, double-blind, placebo- controlled study to evaluate sotatercept when added to background PAH therapy in newly diagnosed intermediate- or high-risk PAH patients. Sotatercept is an investigational therapy that is not approved for any use in any country.
Slide 52: Enrichment Benefits of Risk Algorithms for PAH Clinical Trials
Enrichment Benefits of Risk Algorithms for Pulmonary Arterial Hypertension Clinical Trials HYPERION Trial Enriched for Risk Scores Measurements and Main Results: Conclusions:
Slide 53: REVEAL Lite Risk Score
REVEAL Lite 2 Risk Score REVEAL 2 B. REVEAL Lite 2 Lite = RISK SCORE Survival Probability 1.0 0.8 0.6 0.4 0.2 Low (n= 960, [events = 123); 83, [events = 231]); HR (95% Cl 2.267 (1.822, 2.822) P-value: <.0001 686, [events = 365]); HR (95% Cl 6.355 (5.175, 7.804) P-value: <,0001 T T T T T T T T T 12 1
Slide 54: Treatment Algorithm From 6th World Symposium on PH
Treatment Algorithm From 6th World Symposium on Pulmonary Hypertension for Treated Patients1 Structured follow-up Patient already on treatment Reassess after 3 to 6 months of treatment Consider referral for lung transplantation Intermediate or high risk* Triple sequential combination†Low risk* After
Slide 55: Case Studies
Case Studies Case 1 Case 2
Slide 56: Case Studies (Continued): Right Heart Catheterization Hemodynamics
Case Studies (Continued…) Right Heart Catheterization HemodynamicsHemodynamics Case 1 Case 2
Slide 57: Case Studies (Continued): Treatment Course
Treatment Course Case Studies (Continued…)
Slide 58: Case Studies (Continued): Follow-up
Case Studies (Continued…) Follow-up Case 1 Case 2
Slide 59: HYPERION Phase 3 Trial Inclusion Criteria
HYPERION Phase 3 Trial Inclusion Criteria Key Inclusion Criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class II or III • Up to 6 months from diagnosis • Intermediate- and high-risk scores (REVEAL Lite 2) • Baseline RHC with PVR ≥4 Wood units • Baseline 6-minute walk distance ≥150
Slide 60: HYPERION Phase 3 Trial Design Schema
HYPERION Phase 3 Trial Design Schema Randomization 1:1 (up to 4 weeks) N = 662 Primary Endpoint Analysis
Slide 61: HYPERION Primary Endpoint
HYPERION Primary Endpoint Time to Clinical Worsening, defined as the first confirmed morbidity event or death. The events that will comprise this endpoint include the following: • All-cause death • Non-planned PAH-related hospitalization of ≥24 hours in duration • Atrial septostomy • Lung transplant
Slide 62: HYPERION Secondary Endpoints
HYPERION Secondary Endpoints Secondary Endpoints • Multicomponent improvement endpoint measured by the proportion of participants achieving all of the following at 24 weeks as compared to baseline: Improvement in 6MWD (increase ≥ 30 m) Improvement in NT-proBNP (decrease in NT-proBNP ≥ 30% or mainten
Slide 63: Marc Humbert, MD, PhD
Professor of Respiratory Medicine at the Université Paris-Saclay in Le Kremlin-Bicêtre, France; Director of the Department of Respiratory and Intensive Care Medicine, French Pulmonary Hypertension Reference Centre, Hôpital Bicêtre, Assistance Publique Hôpitaux de Paris, France *Dr. Humbert is an inv
Slide 64: ZENITH Phase 3 Study
A Phase 3, randomized, double-blind, placebo- controlled study to evaluate sotatercept when added to maximum tolerated background PAH therapy on time to first event of all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours, in participants with WHO FC IV PAH or
Slide 65: PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision
PAH Phase 3 Clinical Development Plan Supports Backbone Therapy Vision ZENITH Patient Population Newly diagnosed stable double combination background therapy Stable background therapy (mono, double, or triple) Stable maximum background therapy
Slide 66: PAH Functional Class Assessments
WHO: World Health Organization PAH Functional Class Assessments NYHA FUNCTIONAL CLASS WHO FUNCTIONAL CLASS DESCRIPTIONS NYHA: New York Heart Association
Slide 67: Survival By NYHA Functional Class
Survival By New York Heart Association (NYHA) Functional Class Survival (%) Time (months) 0 362412 NYHA I/II NYHA III NYHA IV 0 60 100 80 40 20 Survival (%) # at risk: NYHA I/II NYHA III NYHA IV 12 37 7 15 48 6 19 70 9 23 79 11 24 86 10 26 88 13 27 89 17
Slide 68: A PAH Patient in Need of a Fourth Pathway
A PAH Patient in Need of a Fourth Pathway BMPR2
Slide 69: Baseline and Initial Management
Baseline REVEAL Lite 2 NYHA functional class IV 2 6-MWD, m 100 1 Systolic blood pressure, mmHg 100 1 Heart rate, bpm 100 1 NT-proBNP, ng/L 3000 2 Renal failure No 0 RAP, mm Hg CI, L/min/m2 SvO2, % 19 1.6 50 - REVEAL Lite 2 = 13 (2 + 1 + 1 + 1 + 2 + 6) Status: High risk Idiopathic PAH IV diuretics IV
Slide 70: Evaluation at 6 Months
Baseline 6 months NYHA functional class IV III 6-MWD, m 100 300 Systolic blood pressure, mmHg 100 100 Heart rate, bpm 100 100 NT-pro BNP, ng/L 3000 1400 Renal failure No No RAP, mm Hg CI, L/min/m2 SvO2, % 19 1.6 50 11 2.2 58 REVEAL Lite 2 = 11 (1 + 0 + 1 + 1 + 2 + 6) Status: High risk idiopathic PAH
Slide 71: ZENITH Phase 3 Trial Inclusion Criteria
ZENITH Phase 3 Trial Inclusion Criteria ZENITH Key Inclusion Criteria • Adults ≥18 years old • WHO Group 1 PAH • WHO Functional Class III or IV • Reveal Lite 2 Risk Score of ≥ 10 • Baseline RHC with PVR ≥5 Wood units • Stable on maximum tolerated background PAH therapy
Slide 72: ZENITH Phase 3 Trial Design Schema
ZENITH Phase 3 Trial Design Schema ZENITH Randomization 1:1 (up to 4 weeks) N = up to 166 Primary Endpoint Analysis
Slide 73: Primary and Key Secondary Endpoints
Primary and Key Secondary Endpoints ZENITH Primary Endpoint • Time to all-cause death or time to PAH-related hospitalization of ≥ 24 hours Key Secondary Endpoints • Overall survival • Transplant- and ECMO-free survival
Slide 74: Additional Secondary Endpoints and Analyses
Additional Secondary Endpoints and Analyses ZENITH • Change from baseline in REVEAL Lite 2 risk score • Proportion of participants achieving a low or intermediate (≤7) REVEAL Lite 2 risk score • Change from baseline in NT-proBNP • Change from baseline in PVR • Change from baseline in mean pulmonary
Slide 75: Mardi Gomberg-Maitland, MD, MSc
Professor of Medicine and Director of the Pulmonary Hypertension Program at The George Washington University Hospital *Dr. Gomberg is an investigator in multiple ongoing and planned Acceleron- sponsored clinical trials and a paid consultant to Acceleron. M A R D I G O M B E R G - M A I T L A N D , M
Slide 76: Clinical Classification of Pulmonary Hypertension: WHO Groups
Clinical Classification of Pulmonary Hypertension: WHO GROUPS 1. Pulmonary arterial hypertension 2. Pulmonary hypertension due to left heart disease 3. Pulmonary hypertension due to lung diseases and/or hypoxia 4. Pulmonary hypertension due to pulmonary artery obstructions 5. Pulmonary hypertension
Slide 77: Global Perspective: PH Left Heart Disease Worldwide
Global Perspective – PH: 40-50% PH Left Heart Disease Worldwide Lancet Respir Med
Slide 78: What are the Causes of Group 2 PH
What are the Causes of Group 2 PH Chronic systolic LV heart failure: the heart squeeze is down= Heart Failure Reduced Ejection Fraction (HFrEF)- dilated LV Chronic diastolic LV heart failure: the heart relaxes poorly= Heart failure Preserved Ejection Fraction (HFpEF)- thick LV Heart failure fr
Slide 79: Group 2: Left Heart Disease
Eur Respir J. Group 2: Left Heart Disease Heart Failure With Preserved Ejection Fraction (HFpEF) Heart Failure With Reduced Ejection Fraction (HFrEF) Valvular Heart Disease Dysfunction/Congenital/ Acquired LH Inflow/ Outflow Tract Prognosis Symptoms Cause / Risk Factors Description
Slide 80: Combined Pre-post Capillary PH: 2 Hits
LV Injury and Dysfunction LVEDP, PAWP, MR, Neurohormones, Cytokines Pulmonary Endothelial Cell Dysfunction: ET, NO & cGMP Pulmonary Vasoconstriction/Pulmonary Vascular Remodeling Pulmonary Hypertension RV Remodeling and Failure Morbidity and Mortality Pulmonary Venous Hypertension Pulmonary Arterial
Slide 81: High Mortality with HFpEF-PH
High Mortality with HFpEF-PH: As Bad As End Stage Lung Cancer 340 WHO Group II PH patients with any follow-up from baseline diagnosis. 2 year survival from baseline diagnosis by score Worse than Group 1 PAH T4 NSCLC (Stage 3B or worse) Variable HR (95% CI) Systolic Blood Pressure ≤ 113 mmHg 2.6 (1.7
Slide 82: NYHA Functional Class: Symptom Rating Scale
NYHA Functional Class: Symptom Rating Scale Class 1 Class 4 Class 3 Class 2
Slide 83: Large Unmet Need: No Treatment for Most Group 2 PH
Large Unmet Need: Most Group 2 PH from HFpEF and there is NO Medical/Surgical Treatment Mitral Valve Disease MVD (~46%) HighLow Heart Failure Reduced Ejection Fraction HFrEF (~15%) HighLow Heart Failure Preserved Ejection Fraction HFpEF (~39%) No surgical or medical solution
Slide 84: Recent Randomized Controlled Trials in PH Due to LHD
Recent Randomized Controlled Trials Targeting PDE5/NO and ET Pathways in PH Due to LHD First Author or Study Study Drug Dose Subjects n Duration Population Primary Outcome Result Guazzi1 Sildenafil 50 mg, t.i.d. 44 12 months HFpEF PVR, RV performance, CPET Improvement LEPHT2 Riociguat 0.5, 1 or 2 mg
Slide 85: Limitations/Challenges of PAH-Approved Vasodilation Treatment
Limitations/Challenges PAH-Approved Vasodilation Treatment
Slide 86: Current Treatments for Group 2 PH Patients are Limited
Treatment Options Rare Heart Transplantation or Supportive Care PAH-Approved Treatment Use in Select Patients Treat Underlying Left Heart Disease Lifestyle Interventions to Mitigate PH Evaluate for Pharmacotherapy Emerging Therapies Current Treatments for Group 2 PH Patients are Limited with No Appr
Slide 87: ESC/ERS Guidelines
ESC/ERS Guidelines Use of PAH-approved therapies is NOT recommended (currently approved)
Slide 88: Scientific Rationale and Preclinical Research in WHO Group 2 PH
Patrick Andre, PhD Head of Biology, Acceleron S C IEN TI F IC R ATI ON AL E AN D P R EC L IN IC A L R ES EAR C H IN W H O GR OU P 2 PH
Slide 89: Group 2 PH: Development and Similarities with PAH
Group 2 PH – Development & Similarities with PAH Gp2 PH: Represents a sub-phenotype of PH-LHD that shares physiological and molecular (hemodynamic & genetic) similarities with PAH: Systolic/Diastolic PA pressure; mPaP, PVR; Gene-ontology J Am Coll Cardiol 2016; 68: 2525-2536. Doi:10.1016/j.jacc.2016
Slide 90: PAH and Group 2 PH Similarities: Activin A Levels
PAH – Group 2 PH Similarities: Activin A Levels are Associated with Disease Severity • Human Genetics and Pharmacological Evidence involving the Activin Pathway • Mice
Slide 91: Activin A as a Key Driver of the Disease
PAH – Group 2 PH Similarities: Activin A as a Key Driver of the Disease • Mice Genetics and Pharmacological Evidence involving the Activin Pathway
Slide 92: ZSF1 Obese Rat Model of HFpEF-PH
ZSF1 Obese Rat Model Recapitulates Key Pathological Features of HFpEF-PH • • • M. Ob. F. Ob. PLOS ONE | https://doi.org/10.1371/ journal.pone.0232399 E/ e’
Slide 93: RAP-011 Aim & Approach
RAP-011 Vehicle Aim & Approach Aim • Obese ZSF1 Rat Approach SU5416 Echo Fasting glucose • Echo • Hemodynamics • GTT Histology
Slide 94: RAP-011 Improves Diastolic Function in HFpEF-PH Model
Results: RAP-011 Improves Diastolic Function, Reduces Left Heart Remodeling in Sugen/ZSF1 - HFpEF-PH Model Reduced Stiffness p<0.05 p<0.01 p<0.0001. E/E’: LVM:
Slide 95: RAP-011 Reduces RVSP, Improves RV Function
Results: RAP-011 Reduces RVSP, Improves RV Function in ZSF1 HFpEF-PH Model Am J Respir Crit Care Med 2021;203;A3649 Wk 22 p<0.05 p<0.01. RVSP: RVFWT
Slide 96: Summary
Summary Preclinical pharmacological evaluation in HFpEF model of left heart disease: • • • Consistent results in additional preclinical models: • • Findings support clinical evaluation of sotatercept in patients with Group 2 PH Protective effects observed at “PAH-effective doses” •
Slide 97: Phase 2 Study of Sotatercept in CpcPH (HFpEF, WHO Group 2 PH)
Mardi Gomberg-Maitland, MD, MSc* Professor of Medicine and Director of the Pulmonary Hypertension Program at The George Washington University Hospital A Phase 2, double blind, randomized, placebo- controlled, parallel-group study of sotatercept in patients with combined pre- and post-capillary pulmo
Slide 98: Patient Case Presentation
Patient Case Presentation NYHA Class III NTproBNP was elevated at 7,000 ug/ml,
Slide 99: Patient Case Presentation: ECHO
Patient Case Presentation: ECHO
Slide 100: Patient Case Presentation: Hemodynamics
Patient Case Presentation: Hemodynamics Her RHC demonstrated CpcPH Elevated right heart, pulmonary, and left heart pressures with an elevated pulmonary vascular resistance She was admitted for optimization with planned outpatient screening for the CADENCE trial PA 70/28/42 PCWP 18 PVR 4.8
Slide 101: CADENCE Phase 2 Trial Inclusion Criteria
CADENCE Phase 2 Trial Inclusion Criteria Key Inclusion Criteria • NYHA functional class II or III • Baseline right heart catheterization with Pulmonary vascular resistance ≥4 Wood units, Mean pulmonary arterial pressure >25, Pulmonary capillary wedge pressure >15 and <30 • 6-minute walk distance ≥10
Slide 102: CADENCE Phase 2 Trial Design Schema
CADENCE Phase 2 Trial Design Schema Randomization 1:1:1 (24 weeks) Placebo Sotatercept 0.3mg/kg (18 months) (4 weeks) Sotatercept 0.3 mg/kg Sotatercept 0.3 mg/kg Sotatercept 0.3mg/kg to 0.7 mg/kg after 3rd cycle Primary Endpoint Analysis
Slide 103: CADENCE 24-week Endpoints
CADENCE 24-week Endpoints Primary Endpoint • Change in pulmonary vascular resistance from baseline to week 24 Key Secondary Endpoint • Change in 6-minute walk distance from baseline to week 24
Slide 104: CADENCE Additional Endpoints
CADENCE Additional Endpoints • Clinical Worsening Events: Number of Clinical Worsening event, time to Clinical Worsening and number of participants with first Clinical Worsening event were measured. - Number of Clinical Worsening Events at 24 weeks and 48 weeks. - Number of participants with first C
Slide 105: Jay Backstrom, Head of Research & Development
J AY B AC KS TR OM , MD , M PH H E A D O F R E S E A R C H & D E V E L O P M E N T
Slide 106: Sotatercept Development in Pulmonary Hypertension
Sotatercept Development in Pulmonary Hypertension GROUP 1 Pulmonary Arterial Hypertension GROUP 2 Left Heart Disease GROUP 3 Interstitial Lung Disease TBD WHO PH Group Scientific and Preclinical Evaluation Ongoing ZENITH
Slide 107: Sotatercept & Pulmonary Hypertension Focused Q&A Session
Sotatercept & Pulmonary Hypertension Focused Q&A Session M A R C H U M B E R T , M D , P H D * V A L L E R I E M C L A U G H L I N , M D * M A R D I G O M B E R G , M D , M S c * H A B I B D A B L E J A Y B A C K S T R O M , M D , M P H J A N E T H E P E N A , M D , P H D P A T R I C K A N D R E , P
Slide 108: Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Janethe Pena, MD, PhD Head of Pulmonary Medical Research, Acceleron S Y S TEM IC S C L ERO SI S- A SS OC I AT ED IN TER S TI TI AL L U NG D IS EAS E (S SC - IL D )
Slide 109: Scleroderma/Systemic Sclerosis
Scleroderma/Systemic Sclerosis Scleroderma Localized Scleroderma Systemic Sclerosis (Systemic Scleroderma) Morphea Linear Sclerosis Limited Cutaneous Systemic Sclerosis Diffuse Cutaneous Systemic Sclerosis Systemic Sclerosis Sine Scleroderma
Slide 110: Classification of Systemic Sclerosis
Classification of Systemic Sclerosis
Slide 111: Common Manifestations of Systemic Sclerosis
Common Manifestations of Systemic Sclerosis Skin Gastrointestinal Musculoskeletal Hands Heart Kidney Lungs TGF-b Linked
Slide 112: Overview of SSc-ILD
Overview of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD) Healthy Lung SSc-ILD Lung • Driven by a combination of autoimmunity, fibrosis, inflammation, and vascular injury • Fibrotic scarring of the alveolar wall impedes oxygen transportation and eventual replaces normal pulmonary
Slide 113: SSc-ILD US/EU Prevalence
SSc-ILD US/EU Prevalence >50K PATIENTS
Slide 114: Common Symptoms in Systemic Sclerosis Patients with ILD
Common Symptoms in Systemic Sclerosis Patients with ILD Cough Chest PainDizziness and/or Fainting Exertion Fatigue
Slide 115: ILD is the Leading Cause of Death in Systemic Sclerosis
ILD is the Leading Cause of Death in Patients with Systemic Sclerosis (SSc) 5-year and 10-year Survival Rates by SSc Classification* SSc-related Death and Organ System Involvement* Source: Semin Arthritis Rheum
Slide 116: Treatment Algorithm for SSc-ILD Patients
Treatment Algorithm for SSc-ILD Patients Immunosuppressive therapy nintedanib tocilizumab Additional options (Multiple unapproved agents) HSCT or Lung Transplant
Slide 117: Unmet Need for Patients with SSc-ILD
Unmet Need for Patients with SSc-ILD
Slide 118: Scientific Rationale and Preclinical Research in SSc-ILD
Patrick Andre, PhD Head of Biology, Acceleron S C IEN TI F IC R ATI ON AL E AN D P R EC L IN IC A L R ES EAR C H IN S SC - IL D
Slide 119: Fibrosis is the Hallmark of SSc & SSc-ILD
Fibrosis is the Hallmark of SSc & SSc-ILD SSc-ILD Lungs Oesophagus Heart Kidney Thickened Skin Intestine Raynaud’s TGF-b1 Dantas AT, et al (2016) Dis Markers. Circulating TGF-β1 level is increased in SScTGF-b1
Slide 120: TGF-β-mediated Fibrosis in SSc-ILD
TGF-β-mediated Fibrosis in ILD (SSc) Transcription (TGF-b, Col1A1, a-SMA…) TGF-b
Slide 121: ACE-1334, RAP-1332: Specific Ligand Traps for TGF-β
ACE-1334, RAP-1332: Specific Ligand Traps for TGF-β 1, 3 • ACE-1334 is a homodimeric Fc fusion protein comprised of the extracellular domain of the human TGF-b receptor type II (TGFβRII), linked to a human IgG1 Fc domain • ACE-1334 binds with high affinity to TGF-β1 and TGF-β3 • RAP-1332 is a homodi
Slide 122: The Systemic Bleomycin Mouse Model of SSc-ILD
The Systemic Bleomycin (mini-pump) Mouse Model of SSc-ILD
Slide 123: SSc-ILD Model Evaluation
SSc-ILD Model Evaluation Bleomycin Minipump Treatment Biw, s.c. ✱✱✱✱ ✱✱✱✱ ✱✱✱✱ ✱ Target Engagement
Slide 124: Effect of RAP-1332 on Markers of Pulmonary Fibrosis
Effect of RAP-1332 on Markers of Pulmonary Fibrosis Col1a1 mRNA
Slide 125: The Fra-2 Translational Model of SSc-ILD
The Fra-2 (Fos-related antigen-2) Translational Model of SSc-ILD https://doi.org/10.1016/j.cellsig.2019.109408 Lung Skin F. Fra-2 Fra-2 Fra-2 Tg (Fra-2)WT Eferl R, et al (2008) Proc Natl Acad Sci USA
Slide 126: RAP-1332 Reduces Lung Fibrosis in Fra-2 Tg Model
RAP-1332 Reduces Lung Fibrosis in Fra-2 Tg SSc-ILD Model WT Fra 2 tg w k8 Fra 2 tg /Sa line Fra 2 tg /13 32 0 10 20 30 40 ** # *** Fra2Tg +PBS Fra2Tg +1332 Fra2Tg 8wks WT
Slide 127: RAP-1332 Shows a Trend in Reduced Inflammation in Lungs
RAP-1332 Shows a Trend in Reduced Inflammation in Lungs from Fra-2 Tg Mice WT 8 WK Control FRA2 8 WK FRA2 16 WK PBS FRA2 16 WK RAP-1332 CNIO-FRA2 IHC F4/80 Positive cells (%)
Slide 128: RAP-1332 Summary in SSc-ILD Models
RAP-1332 (ACE-1334 analog) Summary in SSc-ILD Models • • • • •
Slide 129: ACE-1334 Clinical Development Plan in SSc-ILD
AC E-1 33 4 C L I NI C AL D EVEL OP MEN T PL A N IN SS C - IL D Janethe Pena, MD, PhD Head of Pulmonary Medical Research, Acceleron
Slide 130: ACE-1334 in Systemic Sclerosis
ACE-1334 in Systemic Sclerosis ACE-1334 FAST TRACK DESIGNATION ORPHAN DRUG DESIGNATION
Slide 131: ACE-1334 Phase 1 Study Takeaways
ACE-1334 Phase 1 Study Takeaways • Single-ascending dose design • Healthy volunteer subjects • ACE-1334 was generally well tolerated • Strong relationship between dose and pharmacokinetic / pharmacodynamic markers ACE-1334 P H A S E 1
Slide 132: ACE-1334 Phase 1b Study Inclusion Criteria
ACE-1334 Phase 1b Study Inclusion Criteria Inclusion Criteria • Diffuse systemic sclerosis • Modified Rodnan skin score ≥15 • Forced vital capacity ≥50% predicted • Elevated acute phase reactants • Disease duration ≤60 months • Diffusing capacity of the lungs for carbon monoxide ≥40% - ≤89% • Stable
Slide 133: ACE-1334 Phase 1b Study Design
ACE-1334 Phase 1b Study Design Open-label treatment period Randomization 1:1 ACE-1334 dose 2 (mg/kg) Q4W + SOC ACE-1334 dose 1 (mg/kg) Q2W + SOC Go to Phase 2 ACE-1334 dose 4 (mg/kg) Q4W + SOC ACE-1334 dose 3 (mg/kg) Q2W + SOC ACE-1334 dose 6 (mg/kg) Q4W + SOC ACE-1334 dose 5 (mg/kg) Q2W + SOC Conti
Slide 134: ACE-1334 Phase 1b Biomarkers and Quantitative Systems Pharmacology
ACE-1334 Phase 1b Study – Biomarkers and Quantitative Systems Pharmacology Dose-response modeling and evaluation Dose Identification
Slide 135: Phase 2 Trial Design
Phase 2 Trial Design • Dose to be informed by Phase 1b results • Phase 2 will be a randomized, double-blind, placebo- controlled trial design with two ACE-1334 dose arms versus standard of care. • Patient population: systemic sclerosis associated interstitial lung disease • Primary endpoint: forced
Slide 136: Closing Remarks
J AY B AC KS TR OM , MD , M PH H E A D O F R E S E A R C H & D E V E L O P M E N T C L O S I N G R E M A R K S
Slide 137: R&D Day Highlights/Key Takeaways
R&D Day Highlights/Key Takeaways
Slide 138: Closing Q&A Session
Closing Q&A Session H A B I B D A B L E J A Y B A C K S T R O M , M D , M P H J A N E T H E P E N A , M D , P H D P A T R I C K A N D R E , P H D S U J A Y K A N G O R A V I K U M A R , P H D
Slide 139: Thank You
TH A NK YOU ! F O R M O R E I N F O R M A T I O N , P L E A S E V I S I T O U R N E W W E B S I T E